SCHEMBL6380460

SCHEMBL6380460

CC[N]c1cccc(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
KMT2A Q03164 2/20 0.46
ACHE P22303 1/20 0.43
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
PKM P14618 1/20 0.38
MAPK1 P28482 1/20 0.38
THPO P40225 1/20 0.38
CHRM5 P08912 1/20 0.38
GRM5 P41594 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
TAAR1 Q96RJ0 3/20 0.37
NFE2L2 Q16236 1/20 0.37
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
MIF P14174 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7649176 0.83 NPC1 (0.43) NPC1RAB9AKMT2AACHECYP1A2
SCHEMBL7649340 0.77 MGLL (0.40) NPC1RAB9AKMT2AACHEMEN1
SCHEMBL3525971 0.76 HTR3E (0.50) NPC1RAB9AKMT2AACHECYP1A2
SCHEMBL1547811 0.75
SCHEMBL2306420 0.74 ALDH1A1 (0.46) RAB9AKMT2AACHECYP3A4BLM
SCHEMBL11214729 0.74 NOS3 (0.51) KMT2ACYP1A2CYP3A4CYP2D6THPO
SCHEMBL30102203 0.74 KMT2A (0.64) NPC1RAB9AKMT2AACHECYP1A2
SCHEMBL28651876 0.74 KMT2A (0.64) NPC1RAB9AKMT2AACHECYP1A2
SCHEMBL28651874 0.74 KMT2A (0.64) NPC1RAB9AKMT2AACHECYP1A2
SCHEMBL4083264 0.74 NPC1 (0.48) NPC1RAB9AKMT2AACHECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113512029-A Preparation and application of substituted pyrazole compound containing pyrimidinamine 沈阳中化农药化工研发有限公司 2021-10-19 CN claimed
US-20160362427-A1 BRIDGED BICYCLIC KALLIKREIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2016-12-15 US claimed
CN-113105334-B Perovskite single crystal and preparation method and application thereof 上海科技大学 2023-08-22 CN disclosed
CN-113105334-B Perovskite single crystal and preparation method and application thereof 上海科技大学 2023-08-22 CN disclosed
CN-113512029-A Preparation and application of substituted pyrazole compound containing pyrimidinamine 沈阳中化农药化工研发有限公司 2021-10-19 CN disclosed
EP-0988309-B1 C-4''-SUBSTITUTED MACROLIDE DERIVATIVES PFIZER PROD INC (US) 2005-11-23 EP disclosed
EP-1366026-B1 PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES SUMITOMO CHEMICAL CO (JP) 2004-12-01 EP disclosed
US-6420536-B1 COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF BACTERIAL AND PROTOZOAN INFECTIONS PFIZER INC 2002-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160362427-A1 BRIDGED BICYCLIC KALLIKREIN INHIBITORS KLKB1, KLK1, KLK2 NPC1 1491/4885RAB9A 2869/4885KMT2A 1323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.